DURECT Corp. (DRRX) Announces Third Quarter Financial Results; CEO Comments on Outlook for REMOXY®
DURECT Corporation (NASD: DRRX), an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, recently reported its financial results for the third quarter ended September 30, 2008. Total quarterly revenue reached $6.6 million, compared to $4.9 million for the same period in 2007, and the company’s net loss for the quarter was reported at $9.2 million, or a loss of $0.11 per share, compared to a net loss of $7.9 million, or a loss of $0.11 per share, for the corresponding period one-year earlier. The company plans to earn its first product royalties from REMOXY®, a…